LCM
NAVB

Laurion Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Laurion Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,920
Closed -$233K – 1184
2016
Q2 		$233K Buy
+21,920
New +$431K ﹤0.01% 710

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Laurion Capital Management's NAVB Position: Q3 2016 in Review

Laurion Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 21,920 shares — an estimated $233K sold.

Laurion Capital Management first reported a position in NAVB in Q2 2016 and held it in 1 quarter. The position peaked at $233K in Q2 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

  • Laurion Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • Laurion Capital Management sold 21,920 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $233K.
  • Laurion Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 1 quarter.
  • Laurion Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $233K in Q2 2016.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Laurion Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.